{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Grade 3 or Higher"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Grade 4 or Higher"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.","groups":[{"description":"Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"All 34 participants were evaluable for adverse events.","reportingStatus":"POSTED","timeFrame":"Participants will be evaluated every cycle during treatment","title":"Determine the Clinical Toxicities of This Drug in This Participant Population.","type":"SECONDARY","unitOfMeasure":"participants"}